Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony W Tolcher

Showing results (71-80 of 123) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancerAnthony W Tolcher, Desiree Hao, Johann de Bono, et al.
Investigational New Drugs|December 3, 2017
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancerJonathan W Goldman, Lee S Rosen, Anthony W Tolcher, et al.
Cancer Chemotherapy and Pharmacology|December 4, 2013
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumorsAnthony W Tolcher, Wendi V Rodrigueza, Drew W Rasco, et al.
Cancer Chemotherapy and Pharmacology|February 10, 2011
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumorsAlejandro D Ricart, Edward A Ashton, Matthew M Cooney, et al.
Cancer Chemotherapy and Pharmacology|February 7, 2013
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumorsShahneen K Sandhu, Kyri Papadopoulos, Peter C Fong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitorDesirée Hao, Lisa A Hammond, S Gail Eckhardt, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2009
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignanciesChia-Chi Lin, Muralidhar Beeram, Eric K Rowinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancerChris H Takimoto, Lisa A Hammond-Thelin, Jane E Latz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2017
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid TumorsAnthony W Tolcher, Mario Sznol, Siwen Hu-Lieskovan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomasJohann S de Bono, Anthony W Tolcher, Andre Forero, et al.
Pageof 13

Showing results (71-80 of 123) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancerAnthony W Tolcher, Desiree Hao, Johann de Bono, et al.
Investigational New Drugs|December 3, 2017
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancerJonathan W Goldman, Lee S Rosen, Anthony W Tolcher, et al.
Cancer Chemotherapy and Pharmacology|December 4, 2013
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumorsAnthony W Tolcher, Wendi V Rodrigueza, Drew W Rasco, et al.
Cancer Chemotherapy and Pharmacology|February 10, 2011
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumorsAlejandro D Ricart, Edward A Ashton, Matthew M Cooney, et al.
Cancer Chemotherapy and Pharmacology|February 7, 2013
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumorsShahneen K Sandhu, Kyri Papadopoulos, Peter C Fong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitorDesirée Hao, Lisa A Hammond, S Gail Eckhardt, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2009
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignanciesChia-Chi Lin, Muralidhar Beeram, Eric K Rowinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancerChris H Takimoto, Lisa A Hammond-Thelin, Jane E Latz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2017
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid TumorsAnthony W Tolcher, Mario Sznol, Siwen Hu-Lieskovan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomasJohann S de Bono, Anthony W Tolcher, Andre Forero, et al.
Pageof 13